SUPREMUS MEDITECH LIMITED

Executive Summary

SUPREMUS MEDITECH LIMITED is a dormant entity with no financial activity or assets, resulting in no demonstrated ability to service credit obligations. The company’s financial position is negligible, and cash flow is non-existent, making it unsuitable for credit extension at this time. Continued monitoring for any operational commencement or financial improvement is recommended before reconsidering credit facilities.

SUPREMUS MEDITECH LIMITED - Analysis Report

Company Number: 13910635

Analysis Date: 2025-07-20 16:58 UTC

1. Credit Opinion: DECLINE
   SUPREMUS MEDITECH LIMITED is a dormant company with no trading activity or financial movement reported since incorporation in 2022. The balance sheet shows negligible net assets (£0.30) and zero cash balances, indicating no operational revenue or capital generation. There is no evidence of trading history or financial performance to support creditworthiness or debt servicing capability. Given the absence of financial data demonstrating viability or cash flow, the risk of extending credit is very high.

2. Financial Strength:
   The company’s financial statements confirm a dormant status with virtually no assets or equity beyond the nominal share capital. Net assets and shareholders' funds remain at £0.30, indicating no business operations or value creation. There are no liabilities reported, but this reflects inactivity rather than financial strength. The lack of fixed or current assets and zero cash reserves means the company has no financial buffer or capacity to absorb shocks.

3. Cash Flow Assessment:
   Cash flow is effectively nil with zero cash balances reported over the past three years. The dormant status implies no revenue generation, no working capital, and no liquidity to support operational or financing needs. There is no evidence of cash inflows or outflows, so the company cannot demonstrate any ability to meet short-term obligations or service debt.

4. Monitoring Points:

• Monitor for any change from dormant to active trading status with associated financial filings.
• Watch for submission of future accounts indicating operational activity or improved asset base.
• Review any changes in ownership or management that might signal a strategic shift or capital injection.
• Monitor payment of statutory filings to ensure ongoing compliance and avoid regulatory risk.